Registry of biomedical companies:
[3] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 460 active entries
281 Kercheval Avenue
Grosse Pointe Farms, 48236
United States of America, Michigan
Phone: +1-313-263-4887
E-Mail:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Description:
SciTech Development, LLC A clinical-stage, specialty oncology pharmaceutical company Revolutionizing how safe and promising yet challenged drugs can be delivered to kill cancer ST-001 nanoFenretinide: Lead Drug Candidate and Clinical Trial Ready Through a combination of innovative science and advanced nanotechnology, SciTech has developed ST-001nanoFenretinide, a patented formulation that is clinical trial ready for T-cell lymphomas (a form of non-Hodgkin lymphoma). Problem: Low Drug Bioavailability Severely Limits Clinical Use Many cancer drugs have low bioavailability (absorption) due to water insolubility. This results in sub-therapeutic dosing levels and insufficient amounts of the drug delivered to the cancer cells. Increasing the dose can lead to unacceptable toxicity levels and side effects. Fenretinide’s low bioavailability presented challenges for use in cancer and remained unsolved - until now. Solution: An Effective Delivery Platform and ST-001 nanoFenretinide ST-001 is a nanoparticle combination of fenretinide and biocompatible phospholipids, allowing rapid infusion (IV) of high-dose fenretinide to solve bioavailability challenges, avoid triglyceride (or fatty) toxicity, and optimize therapeutic efficacy. ► Overcomes drug delivery and bioavailability challenges seen with fenretinide ► Safely achieves therapeutically effective dosing ► Avoids toxic side effects seen with other delivery systems and formulations ► Delivers a 6-fold higher formulation strength than conventional IV formulations ► Safely delivers at least a 15-fold higher concentration of fenretinide to target cancer cells than other reference formulations ► Enables potential use in numerous other cancers types ST-001 Clinical Trials ► FDA approved, accelerated Phase 1a/b clinical trial for T-cell lymphoma ► Clinical trials beginning in Q4/2023, with several major medical centers ► Institutional Review Board (IRB) approvals: Required for patient recruiting ► Successfully manufactured cGMP clinical supply of ST-001 with our contract drug manufacturing partner SDP: SciTech Nanoparticle Drug Delivery Platform ► Patented nanoparticle drug delivery platform (SDP) aims to solve bioavailability and toxicity challenges ► Uses safe phospholipids to maintain or improve safety profiles ► Can be utilized to increase SciTech’s product pipeline in various other cancers ► May be used to formulate other similarly challenged therapeutic agents
Selected Categories:
Last update of this entry: October 24, 2023
|